Journal of hypertension
-
Journal of hypertension · Apr 2016
Sympathetic denervation facilitates L-type Ca2+ channel activation in renal but not in mesenteric resistance arteries.
Sympathetic denervation enhances agonist-induced vasoconstriction. This effect may involve altered function of signaling mechanisms such as Rho kinase (Rock) and L-type Ca channels downstream from vasoconstrictor receptors. We tested if enhanced Rock and L-type calcium channel activation contribute to exaggerated norepinephrine-induced vasoconstrictions in renal and mesenteric resistance arteries after sympathectomy. ⋯ Sympathetic denervation enhances L-type Ca channel-dependent signaling in renal but not in mesenteric arteries. This effect may be partly explained by the decreased VSMC membrane potential in denervated renal arteries.
-
Journal of hypertension · Mar 2016
Observational StudyAngiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
Renin-angiotensin-aldosterone system blockers are the preferred antihypertensive medications in patients with diabetes and prior stroke. This study aimed to compare the effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in terms of major adverse cardiac events (MACEs) in patients with diabetes who survived ischemic stroke. ⋯ Our study supports the hypothesis that the risks of MACEs and two additional secondary outcomes in patients with diabetes who survived ischemic stroke did not differ according to ACEI versus ARB use.
-
Journal of hypertension · Dec 2015
Retraction Of PublicationReduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients: Retraction.
J Hypertension 2008, 26:1037–1042. The following authors, Drs A. M. ⋯ An investigation by the Research Conduct Office of the Baker Heart and Diabetes Institute found irregularities in a study, including falsification of patients' records and misrepresentation of results, from which this article was derived. On the basis of this investigation the Baker Heart and Diabetes Institute strongly supports retraction and points out the co-authors asking for retraction were found not be involved in the research misconduct. The article is retracted.
-
Journal of hypertension · Jul 2015
Review Meta Analysis Comparative StudyEffects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses.
We have recently published an overview and meta-analysis of the effects of the five major classes of blood pressure-lowering drugs on cardiovascular outcomes when compared with placebo. However, possible differences in effectiveness of the various classes can correctly be estimated only by head-to-head comparisons of different classes of agents. This has been the objective of a new survey and meta-analysis. ⋯ The results of all available evidence from head-to-head drug class comparisons do not allow the formulation of a fixed paradigm of drug choice valuable for all hypertensive patients, but the differences found may suggest specific choices in specific conditions, or preferable combinations of drugs.
-
Journal of hypertension · Jun 2015
1C.07: PRONEUROTENSIN INDEPENDENTLY PREDICTS CARDIOVASCULAR DISEASE. THE MALMÖ PREVENTIVE PROJECT.
Neurotensin is released from the gut after fat intake and has a role in appetite regulations. Proneurotensin is a stable fragment of the neurotensin precursor hormone and fasting plasma proneurotensin levels have shown to be significantly associated with the development of cardiovascular disease in middle aged participants of the Malmö Diet and Cancer Study. Here, we aimed at replicating the initial findings in an independent second cohort and to extend its validity to an older population. ⋯ Fasting proneurotensin levels are independently associated with the risk of developing cardiovascular disease which replicates the findings in MDC study.